Denali Therapeutics (DNLI) Leases (2019 - 2025)
Historic Leases for Denali Therapeutics (DNLI) over the last 7 years, with Q3 2025 value amounting to $49.4 million.
- Denali Therapeutics' Leases rose 2781.96% to $49.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.4 million, marking a year-over-year increase of 2781.96%. This contributed to the annual value of $47.5 million for FY2024, which is 8248.23% up from last year.
- Denali Therapeutics' Leases amounted to $49.4 million in Q3 2025, which was up 2781.96% from $47.4 million recorded in Q2 2025.
- Denali Therapeutics' 5-year Leases high stood at $50.2 million for Q1 2025, and its period low was $24.5 million during Q2 2024.
- For the 5-year period, Denali Therapeutics' Leases averaged around $33.6 million, with its median value being $30.7 million (2021).
- In the last 5 years, Denali Therapeutics' Leases crashed by 1445.75% in 2023 and then soared by 9834.45% in 2025.
- Denali Therapeutics' Leases (Quarter) stood at $30.7 million in 2021, then fell by 1.0% to $30.4 million in 2022, then dropped by 14.42% to $26.0 million in 2023, then surged by 82.48% to $47.5 million in 2024, then increased by 4.03% to $49.4 million in 2025.
- Its Leases stands at $49.4 million for Q3 2025, versus $47.4 million for Q2 2025 and $50.2 million for Q1 2025.